EGFR and colorectal carcinoma: CRC patients included in clinical trials of anti-IGF1R compounds and Sym004 (a mixture of two monoclonal antibodies—futuximab and modotuximab—that binds epitopes in the EGFR extracellular domain) were not selected based on RAS/BRAF WT in liquid biopsy [8,71,93,94].